Clinical Trials Logo

Cardiovascular Diseases clinical trials

View clinical trials related to Cardiovascular Diseases.

Filter by:

NCT ID: NCT05688579 Enrolling by invitation - Hypertension Clinical Trials

Effect of MRA on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia

EMRACHH
Start date: April 16, 2023
Phase: Phase 4
Study type: Interventional

Elevated aldosterone causes moderate to severe increase in blood pressure, and leads to various target organ damage including cardiovascular ones. Aldosterone has been considered one of the important risk factors for cardiovascular and cerebrovascular diseases. Currently, the use of mineralocorticoid receptor antagonists(MRA) has been proven to reduce blood pressure levels, but long-term prognostic data are lacking in hypertensive patients. Therefore, the purpose of this clinical trial is to assess the effect of MRA on cardiovascular disease in patients with Hypertension and Hyperaldosteronemia.

NCT ID: NCT05677386 Enrolling by invitation - Clinical trials for Cardiovascular Diseases

The DANE-HEART Trial - Computed Tomography Coronary Angiography for Primary Prevention

Start date: March 20, 2023
Phase: N/A
Study type: Interventional

The goal of this randomized controlled clinical trial in asymptomatic individuals with risk factors for cardiovascular disease is to investigate whether a preventive treatment strategy guided by computed tomography coronary angiography (CTCA) provides a patient-centered approach, which ensures optimal protection against serious cardiovascular disease. The main question it aims to answer is: Does preventive treatment guided by CTCA reduce the risk of heart attacks or cardiovascular death as compared to using conventional cardiovascular risk scores. Participants will be randomized to preventive medical therapy and/or invasive intervention guided by either CTCA (intervention group) or Systematic COronary Risk Evaluation (SCORE) 2 model for cardiovascular risk prediction (control group).

NCT ID: NCT05659888 Enrolling by invitation - STEMI Clinical Trials

Comparison of Two Lipid Management Strategies in Very High Risk Patients

PENELOPECTRL
Start date: July 25, 2022
Phase:
Study type: Observational [Patient Registry]

Guideline recommended evidence-based clinical care correlates with improved patient outcomes. In real life care, however, adherence to guideline recommendations remains suboptimal. In real life, patients may receive suboptimal treatment and as a result treatment targets are not always met. To support and improve secondary prevention for cardiovascular disease, PENELOPE and PENELOPE-CTRL are designed to support guideline implementation on lipid management and provide valuable feedback to care-givers on real world data.

NCT ID: NCT05659641 Enrolling by invitation - Clinical trials for Cardiovascular Diseases

The Branch-based Intraoperative Stent System in the Treatment of Stanford A Aortic Dissection(BROAD)

BROAD
Start date: January 18, 2023
Phase: N/A
Study type: Interventional

The purpose of the study was to evaluate the safety and efficacy of a branched type intraoperative stent system for the treatment of Stanford type A aortic dissection

NCT ID: NCT05611021 Enrolling by invitation - Clinical trials for Cardiovascular Diseases

Acute Responses to Arm-Crank Exercise on Cardiovascular Function of Patients With Peripheral Artery Disease

Start date: June 8, 2022
Phase: N/A
Study type: Interventional

The aim of this study is to analyze acute responses of arm-cranking exercise on cardiovascular function of peripheral arterial disease patients and compare it to the main exercise recommendation, walking exercise.

NCT ID: NCT05485961 Enrolling by invitation - Clinical trials for Atherosclerotic Cardiovascular Disease

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis

Start date: October 21, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

This is a 2-part (phase 2b/3) prospective, interventional, multicenter, randomized, double blind, placebo controlled study. Part 1 (phase 2b) is a dose-finding study for CSL300 vs placebo. Part 2 (phase 3) aims to assess the efficacy of CSL300 on CV outcomes and safety in subjects with ASCVD or diabetes mellitus and evidence of systemic inflammation who are undergoing maintenance dialysis.

NCT ID: NCT05472597 Enrolling by invitation - Clinical trials for Cardiovascular Diseases

Continuation of the nuMoM2b Heart Health Study

nuMoM2b-HHS2
Start date: November 29, 2022
Phase:
Study type: Observational

Cardiovascular disease (CVD) is the leading cause of mortality and morbidity in U.S. women at all ages, and large knowledge gaps exist in CVD predictive and preventative strategies for women. The nuMoM2b Heart Health Study (nuMoM2b-HHS) has followed a demographically diverse cohort of women enrolled and richly phenotyped during their first pregnancy, with data and biospecimens prospectively collected for up to 7 years thereafter. The overarching scientific goal of this study is to define the relationship between adverse pregnancy outcomes (APOs) and CVD to optimize CVD prediction, prevention, and treatment strategies for women. Continued follow-up of this observational cohort, building on a foundation of existing high-quality data, biospecimens, and administrative structures with a robust framework for ancillary study development and implementation, provides a unique opportunity to address knowledge gaps regarding the early mechanisms and trajectory of CVD in women.

NCT ID: NCT05339048 Enrolling by invitation - Clinical trials for Cardiovascular Diseases

The Cartagena Cohort Study

CaReS
Start date: October 3, 2020
Phase:
Study type: Observational [Patient Registry]

Cardiovascular and respiratory diseases are the first and third cause of death, respectively. Cardiovascular risk is known to increase in groups with impaired lung function; however, the mechanisms behind this association are not fully understood. The aim of CaReS is to elucidate the shared pathophysiology of impaired lung function and cardiovascular risk, and to investigate the risk factors associated with them. The CaReS Cohort Study includes adults (18-80 years old) from Cartagena de Indias, a tropical city on Colombian Caribbean Coast, where recent population admixture settled a three-hybrid genetic structure (European, African and Ameridian ancestry). At baseline, the cohort will generate extensive data on -omics (e.g., genomics, transcriptomics, metabolomics, and epigenomics), socio-economic wellbeing, lifestyle, medical history, cardiometabolic, inflammatory and liver function markers, as well as objective measures of ventilatory and cardiovascular performance. The cohort will collect data every three years, for a total period of ten years. Prospective risk of cardiovascular disease and chronic obstructive pulmonary disease (COPD) will be investigated, and their risk factors. Throughout the study period, changes in prevalence, and interactions of various risk factors with these changes will also be ascertained. A predictive risk score for cardiovascular and chronic respiratory disability will be built, using cross-sectional and longitudinal data.

NCT ID: NCT05320848 Enrolling by invitation - Clinical trials for Cardiac Rehabilitation

Value of Cardiac Rehabilitation on the Treatment of Cardiovascular Disease

Start date: February 1, 2021
Phase: N/A
Study type: Interventional

Cardiac rehabilitation is a valuable treatment for patients with a broad spectrum of cardiac disease. Current guidelines support its use in patients after acute coronary syndrome, coronary artery bypass grafting, coronary stent placement, valve surgery, and stable chronic systolic heart failure. Its use in these conditions is supported by a robust body of research demonstrating improved clinical outcomes. Despite this evidence, cardiac rehabilitation referral and attendance remains low and interventions to increase its use need to be developed.

NCT ID: NCT05261256 Enrolling by invitation - Clinical trials for Cardiovascular Diseases

Cardiac Impairments Following Pediatric Cardiotoxic Anti-cancer Treatment

Start date: February 1, 2022
Phase:
Study type: Observational

This study aims at investigating the feasibility of recruitment and application of a method regarding early detection of subclinical changes in cardiac health after completion of acute cancer treatment during childhood and adolescence.